作者
Matilde Otero-Losada, Nikolai Petrovsky, Abdallah Alami, James A Crispo, Donald Mattison, Francisco Capani, Christopher Goetz, Daniel Krewski, Santiago Perez-Lloret
发表日期
2023/4/3
来源
Expert Opinion on Drug Safety
卷号
22
期号
4
页码范围
343-349
出版商
Taylor & Francis
简介
Background
Information on neurological and psychiatric adverse events following immunization (AEFIs) with COVID-19 vaccines is limited.
Research design & methods
We examined and compared neurological and psychiatric AEFIS reports related to BNT162b2 (Pfizer-BioNTech) and ChAdOx1 (Oxford-AstraZeneca) COVID-19 vaccines and recorded in the United Kingdom Medicines and Healthcare products Regulatory Agency between 9 December 2020 and 30 June 2021.
Results
As of 30 June 2021, 46.1 million doses of ChAdOx1 and 30.3 million doses of BNT162b2 had been administered. The most frequently reported AEFI was headache with 1,686 and 575 cases per million doses of ChAdOx1 and BNT162b2, respectively. AEFIs more frequently reported after CHAdOx1 compared with BNT162b2 vaccination were Guillain-Barré syndrome (OR, 95% CI = 2.53, 1.82–3.51), freezing (6.66, 3.12–14.22), cluster …
学术搜索中的文章
M Otero-Losada, N Petrovsky, A Alami, JA Crispo… - Expert Opinion on Drug Safety, 2023